Sara Pilotto
University of Verona
CancerInternal medicineOncologyRandomized controlled trialStage (cooking)Lung cancerChemotherapyImmunotherapyLungDiseaseEpidermal growth factor receptorAdenocarcinomaPopulationNon small cellCancer researchBreast cancerClinical trialMedicineBiologyImmune system
Publications 216
#1Martina Lorenzi (UNIPD: University of Padua)H-Index: 2
#2Alessandra Ferro (UNIPD: University of Padua)H-Index: 5
Last. Rita ChiariH-Index: 29
view all 0 authors...
LESSONS LEARNED Osimertinib has confirmed effectiveness in this real-world population of patients with EGFR-mutant advanced non-small cell lung cancer population. Thromboembolic events occur more frequently than previously reported, suggesting a thrombotic diathesis that requires further investigation. Patients with at least three metastatic sites, brain metastases, and symptoms at diagnosis seem to have a worse prognosis. BACKGROUND Osimertinib became the standard treatment for patients with un...
#1Lorenzo Belluomini (University of Verona)H-Index: 4
#2Valeria Dionisi (University of Verona)
Last. Sara Pilotto (University of Verona)H-Index: 22
view all 11 authors...
Abstract null null Background null : Improvement in radiotherapy techniques and expected outcomes, as well as in understanding the underlying biological mechanisms contributing to its action (immunomodulation in primis), led to the integration of this therapeutical approach in the current management of advanced non-small cell lung cancer (NSCLC), not only in oncogene-driven tumors, but also in non-oncogene addicted NSCLC where the combination of platinum-based chemotherapy plus pembrolizumab rep...
#1Fabiana PerroneH-Index: 8
#2Lorenzo Belluomini (University of Verona)H-Index: 4
Last. Silvia RinaldiH-Index: 15
view all 19 authors...
Giving the potential contribute in cancer initiation and progression, lung microbiota represents a promising topic in cancer research, although still unexplored. We performed a systematic literature search to identify clinical studies evaluating lung microbiota composition, its correlation with lung cancer patients' clinico-pathological features and prognosis. Of the identified 370 studies, 21 were eligible and included. Although studies were heterogeneous, lung cancer resulted to be enriched in...
1 CitationsSource
#1Francesco FioricaH-Index: 16
#2Lorenzo Belluomini (University of Verona)H-Index: 4
Last. Carlotta Giorgi (University of Ferrara)H-Index: 61
view all 8 authors...
Abscopal effect has been mentioned for a long time, but only recently a deeper knowledge about underlying mechanisms supporting the interaction between immune system and radiation therapy became available. Furthermore, the introduction of immune-checkpoint inhibitors makes appealing the idea of combining them with radiotherapy (RT) to elicit abscopal effect and ideally revert an intrinsic or acquired resistance. Herein, we present the case of a non-small-cell lung cancer patient undergoing, duri...
#1Antonio RossiH-Index: 9
#2Sara PilottoH-Index: 22
Last. Emilio BriaH-Index: 8
view all 7 authors...
Oncology research has changed extensively due to the possibility to categorize each cancer type into smaller subgroups based on histology and particularly on different genetic alterations due to their heterogeneity. The consequences of this heterogeneity are particularly evident in the management of metastatic non-small-cell lung cancer (NSCLC). This review will discuss the benefits and challenges of incorporating precision medicine into early- through late-phase metastatic NSCLC clinical trials...
#1Luigi CelioH-Index: 20
#2Diego CortinovisH-Index: 25
Last. Alessandra Cassano (UCSC: Catholic University of the Sacred Heart)H-Index: 27
view all 21 authors...
BACKGROUND To reduce the overall exposure to dexamethasone (DEX) in patients receiving cisplatin-based chemotherapy, we evaluated the noninferiority of DEX on day 1, with or without low-dose DEX on days 2 and 3, combined with an oral fixed-dose combination of netupitant and palonosetron (NEPA), compared with the guideline-consistent use of 4-day DEX. PATIENTS AND METHODS In this open-label, multicenter study, chemotherapy-naive patients undergoing high-dose cisplatin (≥70 mg/m2 ), were given NEP...
#1Francesco Passiglia (UNITO: University of Turin)H-Index: 8
#2Michela Cinquini (Mario Negri Institute for Pharmacological Research)H-Index: 18
Last. Jessica Menis (UNIPD: University of Padua)
view all 16 authors...
Purpose null This meta-analysis aims to combine and analyze randomized clinical trials comparing computed tomography lung screening (CTLS) versus either no screening (NS) or chest x-ray (CXR) in subjects with cigarette smoking history, to provide a precise and reliable estimation of the benefits and harms associated with CTLS. null Materials and methods null Data from all published randomized trials comparing CTLS versus either NS or CXR in a highly tobacco-exposed population were collected, acc...
#1Vincenzo Di Noia (UCSC: Catholic University of the Sacred Heart)H-Index: 9
#2Ettore D'ArgentoH-Index: 13
Last. Emilio Bria (UCSC: Catholic University of the Sacred Heart)H-Index: 39
view all 15 authors...
Identifying the patients who may benefit the most from immune checkpoints inhibitors remains a great challenge for clinicians. Here we investigate on blood serum amyloid A (SAA) as biomarker of response to upfront pembrolizumab in patients with advanced non-small-cell lung cancer (NSCLC). Patients with PD-L1 ≥ 50% receiving upfront pembrolizumab (P cohort) and with PD-L1 0–49% treated with chemotherapy (CT cohort) were evaluated for blood SAA and radiological response at baseline and every 9 wee...
3 CitationsSource